Welcome to LookChem.com Sign In|Join Free
  • or
6,8-DIMETHYL[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

18591-75-8

Post Buying Request

18591-75-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

18591-75-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 18591-75-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,5,9 and 1 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 18591-75:
(7*1)+(6*8)+(5*5)+(4*9)+(3*1)+(2*7)+(1*5)=138
138 % 10 = 8
So 18591-75-8 is a valid CAS Registry Number.

18591-75-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 6,8-dimethyl-s-triazolo[4,3-b]pyridazine

1.2 Other means of identification

Product number -
Other names 6,8-dimethyl[1,2,4]triazolo[3,4-b]pyridazine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:18591-75-8 SDS

18591-75-8Relevant academic research and scientific papers

SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

-

Paragraph 00249, (2017/12/14)

The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof.

Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis

Velcicky, Juraj,Miltz, Wolfgang,Oberhauser, Berndt,Orain, David,Vaupel, Andrea,Weigand, Klaus,Dawson King, Janet,Littlewood-Evans, Amanda,Nash, Mark,Feifel, Roland,Loetscher, Pius

supporting information, p. 3672 - 3683 (2017/05/17)

A novel, selective, and efficacious GPR4 antagonist 13 was developed starting from lead compound 1a. While compound 1a showed promising efficacy in several disease models, its binding to a H3 receptor as well as a hERG channel prevented it from further development. Therefore, a new round of optimization addressing the key liabilities was performed and led to discovery of compound 13 with an improved profile. Compound 13 showed significant efficacy in the rat antigen induced arthritis as well as in the hyperalgesia and angiogenesis model at a well-tolerated dose of 30 mg/kg.

TRANSLOCATOR PROTEIN LIGANDS

-

Page/Page column 33, (2009/07/25)

The present invention relates to compounds and methods for imaging translocator protein (18 kDa) (TSPO) expression in a subject. This invention also relates to compounds and methods for the treatment of neurodegenerative disorders, inflammation or anxiety in a subject.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 18591-75-8